Shaily Engineering Plastics Ltd (SHAILY) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company reported a strong quarter with a 34% year-over-year revenue growth, primarily driven by exceptional performance in the Healthcare segment.
- EBITDA margins saw a significant expansion of over 1,000 basis points, reaching 31.8%, reflecting an improved product mix with a higher contribution from IP-led pen platforms.
- The Healthcare segment's revenue grew by 163% YoY, doubling its contribution to the overall revenue mix to 38%, underscoring its role as the primary growth engine.
- Strategic initiatives in the Healthcare segment are progressing well, with the launch of the next-generation GLP-1 device, Shaily Axiom Max, and the signing of four new projects.
- The company is actively expanding its manufacturing capacity for pens from 40 million to 80 million units by the end of FY26 to meet the increasing global demand for GLP-1 devices.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.